5-(4-cyanophenoxy)pentyl chloride | 147983-18-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-(4-cyanophenoxy)pentyl chloride
• 英文别名: 4-(5-chloropentoxy)-benzonitrile；4-(5-chloropentoxyl)-benzonitrile；4-(5-chloropentoxy) benzonitrile；4-(5-chloropentoxy)benzonitrile
• CAS: 147983-18-4
• 化学式: C₁₂H₁₄ClNO
• 分子量: 223.702
• InChiKey: VUMGNEJAKHYWHJ-UHFFFAOYSA-N

物化性质

• 沸点：
  371.5±22.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(4-cyanophenoxy)pentyl chloride 以99的产率得到苯甲腈,4-[(5-碘戊基)氧代]-
  参考文献：
  名称：

  Process for preparing N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy]-pentoxy}-benzamidine

  摘要：

  本发明涉及一种改进的制备N-羟基-4-{5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}苯甲酰胺的方法。

  公开号：

  US07585979B2
• 作为产物：
  描述：

  1-溴-5-氯戊烷 、 4-羟基苯甲腈 以giving 4-(5-chloro-pentoxy)-benzonitrile (4)的产率得到5-(4-cyanophenoxy)pentyl chloride
  参考文献：
  名称：

  Benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same

  摘要：

  本发明涉及新型苯甲酰胺衍生物、其制备方法以及包含它们的药物组合物。本发明的新型苯甲酰胺衍生物对于预防和治疗骨质疏松症、骨折和过敏性炎症性疾病是有用的。

  公开号：

  US08178688B2

文献信息

• [EN] NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING THE SAME<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZAMIDINE, PROCÉDÉ DE PRÉPARATION CORRESPONDANT ET COMPOSITION PHARMACEUTIQUE LES CONTENANT QUI PERMET DE PRÉVENIR OU DE TRAITER L'OSTÉOPOROSE
  申请人：DONG WHA PHARM IND CO LTD

  公开号：WO2009017346A1

  公开（公告）日：2009-02-05

  The present invention relates to novel benzamidine derivatives, a process for the preparation thereof and a pharmaceutical composition for preventing or treating osteoporosis comprising the same. The benzamidine derivatives of the present invention effectively inhibit osteoclast differentiation at an extremely low concentration, and thus can be advantageously used for the prevention and treatment of osteoporosis.

  本发明涉及新型苯甲酰胺衍生物，其制备方法以及包含其的用于预防或治疗骨质疏松症的药物组合物。本发明的苯甲酰胺衍生物在极低浓度下有效抑制成骨细胞的分化，因此可有利地用于预防和治疗骨质疏松症。
• [EN] AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-{5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY }-BENZAMIDINE<br/>[FR] METHODE AMELIOREE SERVANT A PREPARER N-HYDROXY-4{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)-PHENOXY]-PENTOXY}-BENZAMIDINE
  申请人：DONG WHA PHARM IND CO LTD

  公开号：WO2006004368A1

  公开（公告）日：2006-01-12

  This invention relates to an improved method of preparing N-hydroxy-4-5- [4- (5-isopropyl-2-methyl-l, 3-thiazol-4-yl) phenoxy] pentoxy }benzamidine .

  这项发明涉及一种改进的制备N-羟基-4-5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}苯甲酰胺的方法。
• Hydroxyamidine derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05455274A1

  公开（公告）日：1995-10-03

  The invention relates to the compounds of the formula ##STR1## wherein the C(=NOH)-NH.sub.2 group may be in tautomeric form, and pharmaceutically acceptable salts thereof, in which: R.sub.1 is amino or amino which is mono- or disubstituted by a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical, an aromatic radical, and a cycloaliphatic hydrocarbon radical or is amino which is disubstituted by a divalent aliphatic hydrocarbon radical or a said radical interrupted by oxygen; R.sub.2 is hydrogen, halogen, trifluoromethyl, an aliphatic hydrocarbon radical or hydroxy; or R.sub.2 is hydroxy which is etherified by an aliphatic alcohol, araliphatic alcohol, or aromatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; or R.sub.2 is hydroxy which is etherified by an aliphatic alcohol which is substituted by carboxy, by esterified carboxy or by amidated carboxy; X.sub.1 and X.sub.3, independently of one another, are oxygen (--O--) or sulphur (--S--); and X.sub.2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical; and R.sub.3 and R.sub.4, independently of one another, are hydrogen, halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy or hydroxy which is etherified by an aliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB.sub.4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB.sub.4 receptor antagonism.

  该发明涉及以下式的化合物##STR1##其中C(=NOH)-NH.sub.2基团可能处于互变式形式，以及其药学上可接受的盐，其中：R.sub.1是氨基或经由从脂肪烃基、芳基脂肪烃基、芳基和环脂烃基中选择的取代基单取代或双取代的氨基，或者是经由二价脂肪烃基或被氧中断的所述基团双取代的氨基；R.sub.2是氢、卤素、三氟甲基、脂肪烃基或羟基；或者R.sub.2是经由脂肪醇、芳基醇或芳香醇乙醚化的羟基，或者是经由脂肪或芳基羧酸酯化的羟基；或者R.sub.2是经由被羧基置换的脂肪醇乙醚化的羟基，或者是被酯化羧基或酰胺基羧基置换的脂肪醇乙醚化的羟基；X.sub.1和X.sub.3互相独立地是氧(--O--)或硫(--S--)；X.sub.2是可由芳基中断的二价脂肪烃基；R.sub.3和R.sub.4互相独立地是氢、卤素、三氟甲基、脂肪烃基、羟基或者经由脂肪醇乙醚化的羟基，或者是经由脂肪或芳基羧酸酯化的羟基；在上述定义中，芳基可能是，互相独立地，进一步经由卤素、三氟甲基、脂肪烃基、羟基和经由脂肪醇乙醚化或经由脂肪或芳基羧酸酯化的羟基中选择的一个或多个取代基取代；其中环脂烃基可能被脂肪基取代。这些化合物在哺乳动物中对于对LTB.sub.4受体拮抗剂具有选择性，并用于治疗对LTB.sub.4受体拮抗作用产生反应的病症或综合征。
• [EN] NOVEL BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] DÉRIVÉS DE BENZAMIDINE NOUVEAU, PROCÉDÉ DE PREPARATION CORRESPONDANT ET COMPOSITION PHARMACEUTIQUE LES CONTENANT
  申请人：DONG WHA PHARM IND CO LTD

  公开号：WO2006014087A1

  公开（公告）日：2006-02-09

  The present invention relates to novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same. The novel benzamidine derivatives of the present invention are useful for the prevention and treatment of osteoporosis, bone fractures and allergic inflammatory diseases .

  本发明涉及新型苯甲酰胺衍生物，其制备方法以及包含相同物质的药物组合物。本发明的新型苯甲酰胺衍生物可用于预防和治疗骨质疏松症、骨折和过敏性炎症性疾病。
• Arylethers, their manufacture and methods of treatment
  申请人：Ciba-Geigy

  公开号：US05246965A1

  公开（公告）日：1993-09-21

  The invention relates to the compounds of the formula ##STR1## wherein the C(.dbd.NH)--NHR group may be in tautomeric or isomeric form, and pharmaceutically acceptable salts thereof, in which: R is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid; R.sub.1 is a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical and a cycloaliphatic hydrocarbon radical; X.sub.1 and X.sub.3, independently of one another, are oxygen (--O--) or sulphur (--S--); and X.sub.2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical; wherein the phenyl rings of formula I may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; and wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB.sub.4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB.sub.4 receptor antagonism.

  本发明涉及公式##STR1##的化合物及其药学上可接受的盐，其中：C(.dbd.NH)--NHR基团可以处于互变异构或同分异构形式，R为氢或由有机碳酸、有机羧酸、磺酸或氨基甲酸衍生的酰基基团；R.sub.1为从脂肪烃基、芳基脂肪烃基和环烷基脂肪烃基中选择的取代基；X.sub.1和X.sub.3独立地为氧（--O--）或硫（--S--）；X.sub.2为二价脂肪烃基，其可以由芳香基中断；在公式I中的苯环可以独立地进一步由卤素、三氟甲基、脂肪烃基、羟基和由脂肪烷基、芳基脂肪烷基或环烷基醇醚化的羟基或由脂肪烷基或芳基脂肪酸酯化的羟基的一个或多个取代基取代；在上述定义中的芳基可以独立地进一步由卤素、三氟甲基、脂肪烃基、羟基和由脂肪烷基、芳基脂肪烷基或环烷基醇醚化的羟基或由脂肪烷基或芳基脂肪酸酯化的羟基的一个或多个取代基取代；其中环烷基脂肪烃基可以由脂肪烃基取代。这些化合物在哺乳动物对LTB.sub.4受体拮抗作用有反应的情况或综合症的治疗中作为选择性LTB.sub.4受体拮抗剂是有用的。